Q

Qingdao NovelBeam Technology Co Ltd
SSE:688677

Watchlist Manager
Qingdao NovelBeam Technology Co Ltd
SSE:688677
Watchlist
Price: 110 CNY -0.9% Market Closed
Market Cap: ¥13.2B

P/S

23.1
Current
107%
More Expensive
vs 3-y average of 11.1

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
23.1
=
Market Cap
¥8.3B
/
Revenue
¥571.8m

Price to Sales (P/S) ratio shows how much investors pay for each dollar of a company`s sales. It`s calculated by dividing the company`s market value by its total revenue.

P/S
23.1
=
Market Cap
¥8.3B
/
Revenue
¥571.8m

Valuation Scenarios

Qingdao NovelBeam Technology Co Ltd is trading above its 3-year average

If P/S returns to its 3-Year Average (11.1), the stock would be worth ¥53.1 (52% downside from current price).

Statistics
Positive Scenarios
0/4
Maximum Downside
-88%
Maximum Upside
No Upside Scenarios
Average Downside
67%
Scenario P/S Value Implied Price Upside/Downside
Current Multiple 23.1 ¥110
0%
3-Year Average 11.1 ¥53.1
-52%
5-Year Average 12.4 ¥59.29
-46%
Industry Average 4.4 ¥20.99
-81%
Country Average 2.8 ¥13.18
-88%

Forward P/S
Today’s price vs future revenue

Today's Market Cap Revenue Forward P/S
¥8.3B
/
Oct 2025
¥571.8m
=
23.1
Current
¥8.3B
/
Dec 2025
¥583.2m
=
14.3
Forward
¥8.3B
/
Dec 2026
¥698.5m
=
11.9
Forward
¥8.3B
/
Dec 2027
¥835.7m
=
10
Forward

Forward P/S shows whether today’s P/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
P/S
P/E
All Countries
Close

Market Distribution

Higher than 95% of companies in China
Percentile
95th
Based on 7 736 companies
95th percentile
23.1
Low
0 — 1.5
Typical Range
1.5 — 5.4
High
5.4 —
Distribution Statistics
China
Min 0
30th Percentile 1.5
Median 2.8
70th Percentile 5.4
Max 5 034 353.9

Qingdao NovelBeam Technology Co Ltd
Glance View

Market Cap
13.2B CNY
Industry
Health Care

Qingdao NovelBeam Technology Co., Ltd. engages in the research and development of optics technology, the manufacture of optical instruments, and the provision of design solutions for medical, life science, laser, and micro-display projection applications. The company is headquartered in Qingdao, Shandong and currently employs 854 full-time employees. The company went IPO on 2021-02-26. Its main products of medical endoscope equipment include fluorescent endoscopes, fluorescent camera adapters/adaptive lenses, fluorescent light source modules and white light source modules. Its medical endoscopic equipment products are mainly used in abdominal endoscopic surgery such as liver and gallbladder and gastrointestinal surgery. Its optical products mainly include medical optical products, industrial and laser optical products, and biometric products. Among them, the biometric products include fingerprint devices, palmprint devices and related accessories. In addition, the Company also provides technical services and house leasing services. The firm distributes its products both in the domestic market and to overseas markets.

Intrinsic Value
47.77 CNY
Overvaluation 57%
Intrinsic Value
Price ¥110
Q
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett